| 영문 | hypoxia | 한글 | 저산소증 |
|---|---|---|---|
| 설명 | 산소운반과 활용 과정에 장애를 발생하여, 동맥혈 산소함량(PaO2)이 감소하며, 조직 속의 산소가 정상치 이하로 감소한 상태. 대별하면 ① 저산소성저산소증, ② 빈혈저산소증, ③ 울혈저산소증, ④ 조직독성저산소증, ⑤ 수용성 저산소증을 분류된다. 초기증상은 의식혼란, 두통, 어지럼증, 구역, 가쁜 호흡, 빠른 맥 등으로, 증상이 진행하면 청색증(혈증 환원 Hb 가 5g/100mL 이상), 의식소실, 경련, 느린맥, 부정맥, 호흡억제, 심장정지에 이른다. 산소요법, 기계적 인공호흡을 실시한다. 그 종류를 원인별로 분류하면 다음과 같다. ① 저산소성저산소증(hypoxic hypoxia): 동맥혈의 산소분압이 감소되어 초래된 저산소증으로 흡입 공기 중의 산소 농도가 감소한 경우, 호흡 중추억제-기도폐쇄-호흡근마비 등 폐포환기가 감소한 경우, 무기폐-폐렴-폐부종 등 폐포에서의 가스 교환이 부적절하여 일어나는 경우, 고열-신진대사항진 등 조직의 산소 소모가 증가하여 일어나는 경우, 이산화질호(N2O)를 이용한 전신마취 후에 드물게 나타나는 확산성 저산소증 등에 의해 발생할 수 있다. ② 빈혈저산소증(anemic hypoxia) : 혈색소가 정상 이하로 감소한 경우, 일산화 탄소중독처럼 혈색소가 산소를 운반할 수 없는 경우에 나타나는 저산소증으로서 산소분압은 정상 범위 내에 있으나 동맥혈의 산소 함량이 크게 감소되어 있는 경우가 대부분이다. ③ 울혈저산소증(stagnant hypoxia) : 동맥혈의 산소분압은 정상이나 조직의 혈액순환이 장애를 받아 나타나는 저산소증으로 심박출량이 감소하여 오는 경우도 있고, 색전증-외상-혈관수축-정맥폐쇄 등에 의해 발생할 수도 있다. ④ 조직독성저산소증(histotoxic hypoxia) : 사립체의 산소 이용률이 낮아진 경우에 나타난다. 혈관 확장제를 과량 사용하게 되면 세포 내 효소의 독성에 의해 저산소증이 올 수 있다. |
||
| Tc cell | cytotoxic T cell |
|---|---|
| ACS | acrocallosal syndrome; acrocephalosyndactyly; acute chest syndrome; acute confusional state; Alcon C... |
| CA | anterior commissure [Lat. commissura anterior]; calcium antagonist; California [rabbit]; cancer; Can... |
| CI | cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar... |
| CL | capillary lumen; cardiolipin; cell line; centralis lateralis; chemiluminescence; chest and left arm ... |
| CH | Chronic hypoxia |
|---|---|
| H | Hypoxia |
| HYP | Hypoxia |
| HIF-1 | Hypoxia Inducible Factor-1 |
| HIF | Hypoxia inducible factor |
| antireticular cytotoxic serum | An antiserum specific for cells of the reticuloendothelial system. (05 Mar 2000) |
|---|---|
| cytotoxic | <pharmacology> Chemicals that are directly toxic to cells, preventing their reproduction or growth. Cytotoxic agents can, as a side effect, damage healthy, noncancerous tissues or organs which have a high proportion of actively dividing cells, for example, bone marrow, hair follicles. These side effects limit the amount and frequency of drug administration. (16 Dec 1997) |
| cytotoxic cell | Cells of the immune system that inhibit or help to terminate an immune response, e.g., suppressor macrophages and suppressor T-cells. Synonym: cytotoxic cell. (05 Mar 2000) |
| cytotoxic drugs | <pharmacology> Anti-cancer drugs which act by killing or preventing the division of cells. See: chemotherapy. (13 Nov 1997) |
| cytotoxic reaction | An immunologic (allergic) reaction in which noncytotropic IgG or IgM antibody combines with specific antigen on cell surfaces; the resulting complex initiates the activation of complement which causes cell lysis or other damage, or which, in the absence of complement, may lead to phagocytosis or may enhance T lymphocyte involvement. (05 Mar 2000) |
| cytotoxic T-cell | <haematology, immunology> Subset of T lymphocytes (mostly CD8) responsible for lysing target cells and for killing virus infected cells (in the context of Class I histocompatibility antigens). (18 Nov 1997) |
| cytotoxic t-lymphocyte | A type of CD8 or, less often, CD4 lymphocyte that kills diseased cells infected by a specific virus or other intracellular microbe. CTLs interact with MHC class I receptors (see Major Histocompatibility Complex). On infected cells and have the prime role in cellmediated immunity (see). Cytovene: See: Ganciclovir. (09 Oct 1997) |
| cytotoxic T lymphocyte-specific serine protease | <enzyme> Structural sequence given in first source Registry number: EC 3.4.21.- Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II (26 Jun 1999) |
| T cytotoxic cells | Lymphocyte-like effector cells which mediate antibody-dependent cell cytotoxicity. They kill antibody-coated target cells which they bind with their fc receptors. (12 Dec 1998) |
| T-lymphocytes, cytotoxic | Immunised T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (mlc), in vivo during a graft-versus-host (gvh) reaction, or after immunization with an allograft, tumour cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (cml). These cells are distinct from natural killer cells (killer cells, natural) and from killer cells mediating antibody-dependent cell cytotoxicity. (12 Dec 1998) |
| anaemic hypoxia | Hypoxia resulting from a decreased concentration of functional haemoglobin or a reduced number of erythrocytes; it is caused by haemorrhage or anaemia of various types, or by poisoning with CO2, nitrites, or chlorates. (05 Mar 2000) |
| cell hypoxia | A condition of decreased oxygen content at the cellular level. (12 Dec 1998) |
| cerebral hypoxia | A lack of oxygen to the cerebral hemispheres (the brain). Depending on the duration and extent of hypoxia, symptoms can be mild (for example lethargy) or serious neurologic damage can result (for example coma, seizures, death). (27 Sep 1997) |
| hypoxia | Reduction of oxygen supply to tissue below physiological levels despite adequate perfusion of the tissue by blood. (cf. Anoxia). (18 Nov 1997) |
| hypoxia-ischemia | See hypoxia. Ischemia refers to blood flow to cells and organs that is not sufficient to maintain their normal function. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|